Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Completed 3Withdrawn 1Terminated 1Suspended 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 24Triple Negative Breast Neoplasms 11Breast Neoplasms 10Carcinoma, Transitional Cell 9Small Cell Lung Carcinoma 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Neoplasm Metastasis 6Melanoma 6Colorectal Neoplasms 6Lung Neoplasms 5Recurrence 4Neoplasms 4Urinary Bladder Neoplasms 3Lymphoma, B-Cell 3Uterine Cervical Neoplasms 2Stomach Neoplasms 2Solid Tumor 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lymphoma 2Liver Neoplasms 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2Head and Neck Neoplasms 2Carcinoma, Merkel Cell 2Brain Neoplasms 2Advanced Solid Tumor 2Urologic Neoplasms 1Urologic Diseases 1

Interventions

Doxorubicin 13Gemcitabine 10Cyclophosphamide 10pazopanib 8Filgrastim 8Radiotherapy 7Ifosfamide 7Cisplatin 7Irinotecan 6Docetaxel 6Radiation 5Granulocyte Colony-Stimulating Factor 5Etoposide 5Trabectedin 4Magnetic Resonance Spectroscopy 4Celecoxib 4Busulfan 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3sargramostim 3pembrolizumab 3X-Rays 3Sirolimus 3Radiotherapy, Intensity-Modulated 3Paclitaxel 3Neoadjuvant Therapy 3Leucovorin 3Dexrazoxane 3Cryosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Sarcoma × atezolizumab × Clear all
NCT02609984 2020-07-07

IMDZ-C232

Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Terminated
89 enrolled 24 charts
Sarcoma

Liposarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡